Slate Medicines raises $130M to crack injectable migraine drug where others have failed

What's the deal? Slate Medicines, a newly formed biotech based in Raleigh, North Carolina, has raised $130 million in a Series A round to develop a new class of injectable migraine prevention drugs. Slate's lead asset, SLTE-1009, was licensed from Guangzhou-based DartsBio Pharmaceuticals on undisclosed terms.

SLTE-1009 targets a protein called PACAP — a pathway distinct from the CGRP-blocking drugs that dominate the current migraine prevention market. A phase 1 study is expected to launch in mid-2026, with the drug designed for subcutaneous injection and potential at-home dosing.

Why now? More than 37 million people in the US live with migraines, and a significant share do not respond adequately to existing CGRP therapies. That unmet need has kept the search for alternatives active.

Earlier this month, Lundbeck announced positive phase 2b results for its intravenous anti-PACAP antibody, bocunebart — validating the target and signalling that the field is maturing. Slate is betting it can go further by delivering the same class of drug via injection rather than infusion, making it more practical for patients.

What could go wrong? The subcutaneous delivery route is where others have stumbled. Lundbeck stopped development of its own injectable anti-PACAP formulation last year after reviewing trial data. Amgen reported no benefit over placebo for its antibody targeting the PAC1 receptor, and Eli Lilly exited after phase 2. Slate enters a graveyard of failed injection attempts in this drug class.

SLTE-1009 has not yet entered clinical testing, meaning all efficacy and safety data remain ahead of it. The asset was developed by a Chinese biotech and licensed to Slate, adding an additional layer of unknowns around the underlying data package.

The signal: Slate's launch reflects two converging trends. First, the migraine market remains an attractive target despite past failures — the scale of unmet need is large enough that investors keep backing new approaches. Second, China-originated assets are increasingly finding their way into US biotech pipelines through licensing deals, a pattern that has accelerated as Chinese biotechs mature and Western VCs look for differentiated molecules at lower cost.

Slate's founding team — drawn from RA Capital's incubator network, with deep neurology and commercial experience — suggests this is a deliberate platform play, not a one-asset bet. The undisclosed pipeline it references may be the more important long-term story.

Sources:
Fierce Biotech
Yahoo! Finance
Axios
Citeline

A.M.

A.M.